Biodexa Pharmaceuticals Announces ADR Ratio Adjustment
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company focused on developing innovative treatment solutions, has made an important announcement regarding its American Depositary Receipts (ADRs). The company, traded on Nasdaq under the ticker BDRX, is changing its ADR ratio to better align with market compliance requirements.
Details of the ADR Ratio Change
Effective soon, the ratio on the ADRs will shift from one ADR representing a staggering ten thousand ordinary shares to a more streamlined one ADR representing one hundred thousand ordinary shares. This significant adjustment aims to improve the pricing structure of Biodexa's ADRs on the Nasdaq exchange.
Mandatory Exchange for ADR Holders
As part of this ratio change, current ADR holders must surrender their existing ADRs for cancellation. In return, holders will receive a new ADR based on the updated ratio. Specifically, for every ten old ADRs, holders are entitled to one new ADR. This process does not allow for fractional ADRs, thus any fractional entitlements will be aggregated and converted to cash for distribution to the eligible ADR holders.
Impact and Objectives of the Change
The primary goal of this ratio adjustment is to comply with the Nasdaq's minimum bid price requirements, which demand that shares maintain a price above $1.00. By effectively performing a reverse ADR split, Biodexa seeks to boost its share price, encouraging a stronger market presence and providing a steady foundation for future growth.
Reassurance on Ordinary Shares
Importantly, this change to the ADR structure is not expected to affect the underlying ordinary shares of Biodexa Pharmaceuticals. The company remains committed to enhancing value for all stakeholders while navigating regulatory landscapes.
Future Outlook
Biodexa's management recognizes that while this ADR adjustment is a strategic move, there are no guarantees regarding its success in achieving the intended compliance outcomes. The management team is actively monitoring market conditions and has expressed optimism about the future trajectory of the company.
Communication with ADR Holders
To facilitate this transition, Biodexa's appointed Depositary, JP Morgan Chase Bank, N.A., will reach out directly to ADR holders in order to manage the exchange process efficiently. This initiative ensures that holders are well-informed and supported throughout the transition.
Frequently Asked Questions
What is the reason for the ADR ratio change?
The ratio change is intended to help Biodexa comply with Nasdaq's minimum price requirements for its ADRs.
How will this affect current ADR holders?
Current ADR holders will need to exchange their old ADRs for new ones based on the new ratio of 1 ADR for every 10 old ADRs.
When will the ratio change take effect?
The effective date for the newly adjusted ADR ratio is anticipated to be in the near future.
Will my ordinary shares be affected by this change?
No, the change in ADR ratio will not have any impact on Biodexa's ordinary shares.
Who will manage the exchange process?
JP Morgan Chase Bank, N.A. will oversee the exchange of ADRs and provide guidance to ADR holders during this process.
